Published in J Exp Med on December 20, 2010
Cyclophilin A: a key player for human disease. Cell Death Dis (2013) 1.26
Disrupting the EMMPRIN (CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion. Arterioscler Thromb Vasc Biol (2011) 1.02
Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative. Arterioscler Thromb Vasc Biol (2014) 0.92
From Drosophila to humans: reflections on the roles of the prolyl isomerases and chaperones, cyclophilins, in cell function and disease. J Neurogenet (2012) 0.89
p62 binding to protein kinase C ζ regulates tumor necrosis factor α-induced apoptotic pathway in endothelial cells. Arterioscler Thromb Vasc Biol (2012) 0.87
Cyclophilin A is required for angiotensin II-induced p47phox translocation to caveolae in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2013) 0.87
Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease. Cardiovasc Diabetol (2014) 0.83
Identification of activators of ERK5 transcriptional activity by high-throughput screening and the role of endothelial ERK5 in vasoprotective effects induced by statins and antimalarial agents. J Immunol (2014) 0.82
Vinpocetine attenuates lipid accumulation and atherosclerosis formation. Biochem Biophys Res Commun (2013) 0.81
NO donor induces Nec-1-inhibitable, but RIP1-independent, necrotic cell death in pancreatic β-cells. FEBS Lett (2011) 0.81
Glutathione peroxidase-deficient smooth muscle cells cause paracrine activation of normal smooth muscle cells via cyclophilin A. Vascul Pharmacol (2011) 0.81
CD137-CD137L interaction regulates atherosclerosis via cyclophilin A in apolipoprotein E-deficient mice. PLoS One (2014) 0.80
The Novel Extracellular Cyclophilin A (CyPA) - Inhibitor MM284 Reduces Myocardial Inflammation and Remodeling in a Mouse Model of Troponin I -Induced Myocarditis. PLoS One (2015) 0.79
Functions of cyclophilin A in atherosclerosis. Exp Clin Cardiol (2013) 0.78
Potential implications of Apolipoprotein E in early brain injury after experimental subarachnoid hemorrhage: Involvement in the modulation of blood-brain barrier integrity. Oncotarget (2016) 0.77
Pharmacological inhibition of dynamin II reduces constitutive protein secretion from primary human macrophages. PLoS One (2014) 0.76
Genetics of cerebral vasospasm. Neurol Res Int (2013) 0.75
Cyclophilin A enhances macrophage differentiation and lipid uptake in high glucose conditions: a cellular mechanism for accelerated macro vascular disease in diabetes mellitus. Cardiovasc Diabetol (2016) 0.75
Decrease in plasma cyclophilin A concentration at 1 month after myocardial infarction predicts better left ventricular performance and synchronicity at 6 months: a pilot study in patients with ST elevation myocardial infarction. Int J Biol Sci (2015) 0.75
Exposure to atheroma-relevant 7-oxysterols causes proteomic alterations in cell death, cellular longevity, and lipid metabolism in THP-1 macrophages. PLoS One (2017) 0.75
Tet methylcytosine dioxygenase 2 inhibits atherosclerosis via upregulation of autophagy in ApoE-/- mice. Oncotarget (2016) 0.75
Effect of cyclosporin A intervention on the immunological mechanisms of coronary heart disease and restenosis. Exp Ther Med (2016) 0.75
Extracellular Cyclophilin A, Especially Acetylated, Causes Pulmonary Hypertension by Stimulating Endothelial Apoptosis, Redox Stress, and Inflammation. Arterioscler Thromb Vasc Biol (2017) 0.75
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
Atherosclerosis. the road ahead. Cell (2001) 11.88
The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006) 9.61
ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb (1994) 8.54
Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science (1984) 8.01
Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science (1991) 5.76
Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol (2009) 5.28
A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest (2001) 4.98
The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol (2008) 4.20
Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. J Clin Invest (2005) 3.96
Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol (1998) 3.66
Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation (2001) 3.01
Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest (1999) 2.95
Role of Krüppel-like transcription factors in endothelial biology. Circ Res (2007) 2.87
Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation (2003) 2.69
Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation (1998) 2.27
Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med (2009) 2.24
Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci U S A (1992) 2.20
Retracted Characterization of a cytosolic heat-shock protein-caveolin chaperone complex. Involvement in cholesterol trafficking. J Biol Chem (1998) 2.18
Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res (2000) 2.09
Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 1.97
Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem (2002) 1.96
Hemizygous deficiency of Krüppel-like factor 2 augments experimental atherosclerosis. Circ Res (2008) 1.94
Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages. Clin Immunol (2005) 1.91
Cardiovascular complications after renal transplantation and their prevention. Transplantation (2006) 1.86
Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol (1993) 1.85
Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. J Clin Invest (2000) 1.84
Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol (2005) 1.82
Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem (2000) 1.68
Leukocyte chemotactic activity of cyclophilin. J Biol Chem (1992) 1.63
Atheroprotective signaling mechanisms activated by steady laminar flow in endothelial cells. Circulation (2008) 1.61
Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol (2004) 1.61
Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation (2006) 1.53
Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res (2006) 1.52
Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline-directed conformational switch in Itk. Immunity (2004) 1.50
Cyclophilin A participates in the nuclear translocation of apoptosis-inducing factor in neurons after cerebral hypoxia-ischemia. J Exp Med (2007) 1.50
Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation (2008) 1.34
Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation (2001) 1.31
Interaction with glycosaminoglycans is required for cyclophilin B to trigger integrin-mediated adhesion of peripheral blood T lymphocytes to extracellular matrix. Proc Natl Acad Sci U S A (2002) 1.30
Elevated serum cyclophilin levels in patients with severe sepsis. J Clin Immunol (1997) 1.28
Relative reduction of endothelial nitric-oxide synthase expression and transcription in atherosclerosis-prone regions of the mouse aorta and in an in vitro model of disturbed flow. Am J Pathol (2007) 1.28
Understanding abdominal aortic aneurysm. N Engl J Med (2009) 1.27
Endothelial NO synthase overexpression inhibits lesion formation in mouse model of vascular remodeling. Arterioscler Thromb Vasc Biol (2001) 1.24
Preferential chemotaxis of activated human CD4+ T cells by extracellular cyclophilin A. J Leukoc Biol (2007) 1.23
Cyclosporin A inhibits flow-mediated activation of endothelial nitric-oxide synthase by altering cholesterol content in caveolae. J Biol Chem (2004) 1.20
Cyclophilin A is required for CXCR4-mediated nuclear export of heterogeneous nuclear ribonucleoprotein A2, activation and nuclear translocation of ERK1/2, and chemotactic cell migration. J Biol Chem (2007) 1.09
Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase: implications for vascular disease. Trends Cardiovasc Med (2001) 1.03
Prevention of atherosclerosis by interference with the vascular nitric oxide system. Curr Pharm Des (2009) 1.02
Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production. Am J Physiol Endocrinol Metab (2000) 1.02
EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation. Atherosclerosis (2009) 0.99
Cyclophilin A produced by thymocytes regulates the migration of murine bone marrow cells. Cell Immunol (2007) 0.96
Cyclosporin A and atherosclerosis--cellular pathways in atherogenesis. Pharmacol Ther (2010) 0.90
Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions. J Pharmacol Exp Ther (2000) 0.85
Low-density lipoprotein metabolism in rats treated with cyclosporine. Metabolism (1993) 0.78
Lipid abnormalities in stable liver transplant recipients--effects of cyclosporin, tacrolimus, and steroids. Transpl Int (1998) 0.77
Region-specific patterns of vascular remodelling occur early in atherosclerosis and without loss of smooth muscle cell markers. Atherosclerosis (2007) 0.77
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature (2012) 3.80
Flow-induced vascular remodeling in the mouse: a model for carotid intima-media thickening. Arterioscler Thromb Vasc Biol (2003) 2.44
Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) (2005) 2.35
Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res (2003) 2.33
Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med (2009) 2.24
Glutathiolation regulates tumor necrosis factor-alpha-induced caspase-3 cleavage and apoptosis: key role for glutaredoxin in the death pathway. Circ Res (2006) 2.24
The multifunctional GIT family of proteins. J Cell Sci (2006) 2.24
Strain-dependent vascular remodeling: the "Glagov phenomenon" is genetically determined. Circulation (2004) 2.21
Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Circ Res (2008) 2.01
Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation (2007) 1.97
Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nat Cell Biol (2002) 1.94
Flow antagonizes TNF-alpha signaling in endothelial cells by inhibiting caspase-dependent PKC zeta processing. Circ Res (2007) 1.87
Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res (2006) 1.86
Fluid shear stress activates proline-rich tyrosine kinase via reactive oxygen species-dependent pathway. Arterioscler Thromb Vasc Biol (2002) 1.79
Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells. J Clin Invest (2005) 1.77
Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium. Circulation (2006) 1.67
Big mitogen-activated protein kinase (BMK1)/ERK5 protects endothelial cells from apoptosis. Circ Res (2003) 1.66
Bcr kinase activation by angiotensin II inhibits peroxisome-proliferator-activated receptor gamma transcriptional activity in vascular smooth muscle cells. Circ Res (2008) 1.63
Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res (2006) 1.62
Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol (2004) 1.61
Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J Biol Chem (2002) 1.57
Thioredoxin: a key regulator of cardiovascular homeostasis. Circ Res (2003) 1.54
Chronic physiological shear stress inhibits tumor necrosis factor-induced proinflammatory responses in rabbit aorta perfused ex vivo. Circulation (2003) 1.53
Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res (2006) 1.52
Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res (2009) 1.47
Inhibiting p90 ribosomal S6 kinase prevents (Na+)-H+ exchanger-mediated cardiac ischemia-reperfusion injury. Circulation (2006) 1.46
Rho-kinase activation in patients with heart failure. Circ J (2013) 1.45
Strain-dependent differences in responses to exercise training in inbred and hybrid mice. Am J Physiol Regul Integr Comp Physiol (2004) 1.44
GIT1 functions as a scaffold for MEK1-extracellular signal-regulated kinase 1 and 2 activation by angiotensin II and epidermal growth factor. Mol Cell Biol (2004) 1.42
Multiple Beneficial Effects of Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension. Circ J (2016) 1.40
Flow shear stress and atherosclerosis: a matter of site specificity. Antioxid Redox Signal (2011) 1.39
Loss of TR4 orphan nuclear receptor reduces phosphoenolpyruvate carboxykinase-mediated gluconeogenesis. Diabetes (2007) 1.39
Axl, a receptor tyrosine kinase, mediates flow-induced vascular remodeling. Circ Res (2006) 1.37
Vascular remodeling: hemodynamic and biochemical mechanisms underlying Glagov's phenomenon. Arterioscler Thromb Vasc Biol (2007) 1.36
Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation (2008) 1.34
A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci U S A (2005) 1.34
Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes (2005) 1.33
GIT1 is a scaffold for ERK1/2 activation in focal adhesions. J Biol Chem (2005) 1.33
Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy. Cardiovasc Res (2002) 1.33
Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology (2008) 1.32
Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res (2007) 1.31
Flow shear stress stimulates Gab1 tyrosine phosphorylation to mediate protein kinase B and endothelial nitric-oxide synthase activation in endothelial cells. J Biol Chem (2005) 1.31
Sphingosine 1-phosphate transactivates the platelet-derived growth factor beta receptor and epidermal growth factor receptor in vascular smooth muscle cells. Circ Res (2004) 1.29
Angiotensin II and the endothelium: diverse signals and effects. Hypertension (2005) 1.28
Crosstalk coregulation mechanisms of G protein-coupled receptors and receptor tyrosine kinases. Methods Mol Biol (2006) 1.27
Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res (2003) 1.26
Thioredoxin interacting protein: redox dependent and independent regulatory mechanisms. Antioxid Redox Signal (2011) 1.24
Thioredoxin in the cardiovascular system. J Mol Med (Berl) (2006) 1.23
GIT1 mediates Src-dependent activation of phospholipase Cgamma by angiotensin II and epidermal growth factor. J Biol Chem (2003) 1.22
The role of MAP kinases in endothelial activation. Vascul Pharmacol (2002) 1.22
ERK5 activation inhibits inflammatory responses via peroxisome proliferator-activated receptor delta (PPARdelta) stimulation. J Biol Chem (2006) 1.21
Cyclosporin A inhibits flow-mediated activation of endothelial nitric-oxide synthase by altering cholesterol content in caveolae. J Biol Chem (2004) 1.20
Calpain-2 regulation of VEGF-mediated angiogenesis. FASEB J (2006) 1.20
Urokinase plasminogen activator stimulates vascular smooth muscle cell proliferation via redox-dependent pathways. Arterioscler Thromb Vasc Biol (2006) 1.20
Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci U S A (2010) 1.19
Oxidative stress and vascular smooth muscle cell growth: a mechanistic linkage by cyclophilin A. Antioxid Redox Signal (2010) 1.17
Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. Arterioscler Thromb Vasc Biol (2003) 1.17
PI3-kinase activity modulates apo B available for hepatic VLDL production in apobec-1-/- mice. Am J Physiol Gastrointest Liver Physiol (2006) 1.17
Role of p90 ribosomal S6 kinase (p90RSK) in reactive oxygen species and protein kinase C beta (PKC-beta)-mediated cardiac troponin I phosphorylation. J Biol Chem (2005) 1.17
GIT1 mediates thrombin signaling in endothelial cells: role in turnover of RhoA-type focal adhesions. Circ Res (2004) 1.16
Metformin inhibits nuclear receptor TR4-mediated hepatic stearoyl-CoA desaturase 1 gene expression with altered insulin sensitivity. Diabetes (2011) 1.16
Activation of extracellular signal-regulated kinase 5 reduces cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase 3A/inducible cAMP early repressor feedback loop. Circ Res (2007) 1.16
PKCζ mediates disturbed flow-induced endothelial apoptosis via p53 SUMOylation. J Cell Biol (2011) 1.15
BMK1/ERK5 is a novel regulator of angiogenesis by destabilizing hypoxia inducible factor 1alpha. Circ Res (2005) 1.15
Gas6 inhibits apoptosis in vascular smooth muscle: role of Axl kinase and Akt. J Mol Cell Cardiol (2004) 1.15
NAD(P)H oxidase-derived reactive oxygen species regulate angiotensin-II induced adventitial fibroblast phenotypic differentiation. Biochem Biophys Res Commun (2005) 1.14
Thioredoxin: a multifunctional antioxidant enzyme in kidney, heart and vessels. Curr Opin Nephrol Hypertens (2005) 1.13
Hydrogen peroxide activates the Gas6-Axl pathway in vascular smooth muscle cells. J Biol Chem (2004) 1.13
Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res (2007) 1.13
Huh-7 or HepG2 cells: which is the better model for studying human apolipoprotein-B100 assembly and secretion? J Lipid Res (2010) 1.11
Angiotensin II signaling pathways mediated by tyrosine kinases. Int J Biochem Cell Biol (2003) 1.09
Role of osteoprotegerin in arterial calcification: development of new animal model. Arterioscler Thromb Vasc Biol (2007) 1.09
G-protein-coupled receptor kinase interacting protein-1 is required for pulmonary vascular development. Circulation (2009) 1.09
PKCzeta decreases eNOS protein stability via inhibitory phosphorylation of ERK5. Blood (2010) 1.07